Posted by Michael Wonder on 16 Jul 2020
Hanmi’s fatty liver drug won FDA’s fast track designation
16 July 2020 - Hanmi Pharmaceutical said Thursday that the U.S. FDA has granted fast-track designation to its LAPSTriple Agonist (HM15211), a new drug for non-alcoholic steatohepatitis.
One of the components of HM15211, glucagon, directly reduces fatty liver and inhibits fibrosis. Along with glucagon, glucagon-like peptide-1 helps control appetite and insulin secretion, and gastric inhibitory peptide acts as insulin secretion and anti-inflammatory.
